CLINICAL TRIALS PROFILE FOR EPACADOSTAT
✉ Email this page to a colleague
Clinical Trials for Epacadostat
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT01604889 ↗ | A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma | Terminated | Incyte Corporation | Phase 1/Phase 2 | The study design includes an open-label, dose escalation phase followed by a blinded, randomized phase, which combines epacadostat (an oral IDO1 inhibitor) with an approved therapy and compares to approved therapy plus placebo in metastatic melanoma patients. |
| NCT01685255 ↗ | A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy | Terminated | Incyte Corporation | Phase 2 | This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy. |
| NCT01961115 ↗ | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Completed | Incyte Corporation | Phase 2 | This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma. |
| NCT01961115 ↗ | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Completed | National Cancer Institute (NCI) | Phase 2 | This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma. |
| NCT01961115 ↗ | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Completed | University of Virginia | Phase 2 | This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma. |
| NCT01961115 ↗ | Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma | Completed | Fred Hutchinson Cancer Research Center | Phase 2 | This pilot phase II trial studies how well epacadostat and vaccine therapy work in treating patients with stage III-IV melanoma. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vaccines made from peptides and antigens may help the body build an effective immune response to kill tumor cells. Giving epacadostat with vaccine therapy may be an effective treatment for advanced melanoma. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Epacadostat
Condition Name
Clinical Trial Locations for Epacadostat
Trials by Country
Clinical Trial Progress for Epacadostat
Clinical Trial Phase
Clinical Trial Sponsors for Epacadostat
Sponsor Name
